JP2023538366A5 - - Google Patents
Info
- Publication number
- JP2023538366A5 JP2023538366A5 JP2023511947A JP2023511947A JP2023538366A5 JP 2023538366 A5 JP2023538366 A5 JP 2023538366A5 JP 2023511947 A JP2023511947 A JP 2023511947A JP 2023511947 A JP2023511947 A JP 2023511947A JP 2023538366 A5 JP2023538366 A5 JP 2023538366A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- sdcdr3
- sdcdr1
- sdcdr2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066565P | 2020-08-17 | 2020-08-17 | |
| US63/066,565 | 2020-08-17 | ||
| PCT/US2021/046217 WO2022040128A2 (en) | 2020-08-17 | 2021-08-17 | Constrained conditionally activated binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538366A JP2023538366A (ja) | 2023-09-07 |
| JP2023538366A5 true JP2023538366A5 (enExample) | 2024-08-22 |
| JP7832926B2 JP7832926B2 (ja) | 2026-03-18 |
Family
ID=77655705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511947A Active JP7832926B2 (ja) | 2020-08-17 | 2021-08-17 | 制約され、条件付きで活性化された結合タンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240026011A1 (enExample) |
| EP (1) | EP4196503A2 (enExample) |
| JP (1) | JP7832926B2 (enExample) |
| KR (1) | KR20230048146A (enExample) |
| CN (1) | CN116419925A (enExample) |
| AR (1) | AR123266A1 (enExample) |
| AU (1) | AU2021329290A1 (enExample) |
| CA (1) | CA3191431A1 (enExample) |
| CL (1) | CL2023000477A1 (enExample) |
| CO (1) | CO2023002164A2 (enExample) |
| EC (1) | ECSP23018458A (enExample) |
| IL (1) | IL300598A (enExample) |
| MX (1) | MX2023002002A (enExample) |
| PE (1) | PE20230856A1 (enExample) |
| TW (1) | TW202214707A (enExample) |
| WO (1) | WO2022040128A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CN111356700A (zh) | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| AR128593A1 (es) * | 2022-02-23 | 2024-05-22 | Takeda Pharmaceuticals Co | Proteínas de unión condicionalmente biespecíficas |
| WO2024040228A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding proteins |
| WO2024040220A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding fusion proteins |
| KR20250057869A (ko) * | 2022-09-07 | 2025-04-29 | 잭세라 바이오파마슈티컬 (수조우) 씨오., 엘티디. | 항-trop2/egfr 항체 및 이의 용도 |
| CN120835898A (zh) * | 2023-01-05 | 2025-10-24 | 哈珀恩治疗公司 | 用于治疗癌症的trop2靶向三特异性蛋白 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| CN109071667A (zh) | 2016-03-08 | 2018-12-21 | 马弗里克治疗公司 | 可诱导性结合蛋白和使用方法 |
| CN111356700A (zh) * | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| EP4592313A3 (en) * | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
-
2021
- 2021-08-17 EP EP21766347.5A patent/EP4196503A2/en active Pending
- 2021-08-17 WO PCT/US2021/046217 patent/WO2022040128A2/en not_active Ceased
- 2021-08-17 US US18/021,730 patent/US20240026011A1/en active Pending
- 2021-08-17 CN CN202180066644.9A patent/CN116419925A/zh active Pending
- 2021-08-17 AR ARP210102304A patent/AR123266A1/es not_active Application Discontinuation
- 2021-08-17 TW TW110130298A patent/TW202214707A/zh unknown
- 2021-08-17 MX MX2023002002A patent/MX2023002002A/es unknown
- 2021-08-17 KR KR1020237009028A patent/KR20230048146A/ko not_active Withdrawn
- 2021-08-17 JP JP2023511947A patent/JP7832926B2/ja active Active
- 2021-08-17 IL IL300598A patent/IL300598A/en unknown
- 2021-08-17 AU AU2021329290A patent/AU2021329290A1/en not_active Abandoned
- 2021-08-17 PE PE2023000289A patent/PE20230856A1/es unknown
- 2021-08-17 CA CA3191431A patent/CA3191431A1/en active Pending
-
2023
- 2023-02-16 CL CL2023000477A patent/CL2023000477A1/es unknown
- 2023-02-27 CO CONC2023/0002164A patent/CO2023002164A2/es unknown
- 2023-03-16 EC ECSENADI202318458A patent/ECSP23018458A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538366A5 (enExample) | ||
| JP7826370B2 (ja) | 拘束され、条件的に活性化された結合タンパク質 | |
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| US11685780B2 (en) | Single domain antigen binding domains that bind human Trop2 | |
| JP2022524337A5 (enExample) | ||
| JP2022524338A5 (enExample) | ||
| JP7832926B2 (ja) | 制約され、条件付きで活性化された結合タンパク質 | |
| WO2022061594A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| JP2025512865A5 (enExample) | ||
| JP2025527303A (ja) | Ｉｌ－１８融合タンパク質およびｉｌ－１８を産生する方法 | |
| JP2025504909A5 (enExample) | ||
| JP7847284B1 (ja) | 上皮増殖因子受容体を標的とする組成物並びにその製造方法及び使用方法 | |
| Kim et al. | A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants | |
| US12128102B2 (en) | Constrained conditionally activated binding proteins | |
| US20230340159A1 (en) | Constrained conditionally activated binding proteins | |
| TW202304998A (zh) | 使用限制性條件活化之結合蛋白的治療方法 | |
| HK40032913A (en) | Constrained conditionally activated binding proteins |